Generate Biomedicines, Inc.
Ownership
Ownership Structure
Who owns Generate Biomedicines, Inc. (GENB)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 47.1% of the shares are freely tradable; institutional investors hold 76.1%.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| Flagship Ventures Management, Inc. | 48.83 | 62,673,117 | +0.0 | 06/30/2026 |
| FMR Inc | 3.29 | 4,217,524 | +0.0 | 03/31/2026 |
| Capital World Investors | 3.28 | 4,215,632 | +5.3 | 06/30/2026 |
| BRAIDWELL LP | 2.80 | 3,592,999 | +0.0 | 03/31/2026 |
| JPMorgan Chase & Co | 2.30 | 2,947,259 | +0.0 | 03/31/2026 |
| T. Rowe Price Associates, Inc. | 1.64 | 2,109,633 | +0.0 | 03/31/2026 |
| NORGES BANK | 1.63 | 2,094,616 | +0.0 | 06/30/2026 |
| ARCH VENTURE CORP | 1.51 | 1,944,426 | +0.0 | 06/30/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| American Funds SMALLCAP World A | 2.92 | 3,752,630 | +2.8 | 06/30/2026 |
| T. Rowe Price Health Sciences | 1.39 | 1,787,637 | +0.0 | 07/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Insider holdings
| Person | Role | Shares | Value | As of | Type |
|---|---|---|---|---|---|
| Arnold Frances | Director | 231,472 | 3,958,171 $ | Sep 1, 2026 | direct |
Holdings as of each person's most recent SEC Form 4 filing — excluding options and RSUs, which are not shares yet. Holdings may have changed between two filings.
Insiders
Insider Transactions
| Date | Person | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 1, 2026 | Arnold Frances | Director | Sell | 1,000 | 16.00 | 16,002 |
Reportable transactions by officers and major shareholders from SEC Form 4 filings. "Other" includes things like stock grants and option exercises without a buy/sell character. View all insider transactions →
Data as of: September 17, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.